On the stock market since 1980, it operates in the world of health and science. It has 7,700 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
An average decline of 3% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly above the class average — a step short of the very top.
The price looks reasonable next to what the company earns.
There is growth, but not at top-of-the-class tempo.
Clearly above the class average — a step short of the very top.
No real weak spot in any of the five subjects — a balanced report card.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades 54% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 29% — still a thick cushion, though costs have been eating into it lately.
Over the last 3 years, sales fell about 3% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The sales tempo runs behind the sector. Council score: 4/10.
On our five-subject report card, BIO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BIO is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.